ZNF385A

Across TCGA pan-cancer cohorts, ZNF385A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNF385A data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZNF385A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZNF385A expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where ZNF385A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.888	0.387	.004	15	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.778	.015	4	view →
CCRCC	DFS	Median	III,IV	0.121	0.783	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZNF385A–PDAC (DFS)

Open the PDAC breakdown →